Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | WRN | Q14191 | 2/20 | 0.42 |
| ▸ | PTPRE | P23469 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079674 | 0.86 | RAB9A (0.49) | BLMMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL6079515 | 0.84 | BLM (0.42) | BLMMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL6080735 | 0.84 | BLM (0.55) | BLMMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL6079773 | 0.82 | MAPT (0.44) | BLMMEN1KMT2AHTTWRN | |
| SCHEMBL6079234 | 0.82 | ABL1 (0.54) | MEN1KMT2AHTTMAPTNPC1 | |
| SCHEMBL6204115 | 0.79 | PTPRE (0.41) | BLMMEN1KMT2AHTTWRN | |
| SCHEMBL6078996 | 0.79 | BRAF (0.50) | BLMSMN1; SMN2WRNPTPREMAPT | |
| SCHEMBL6078593 | 0.78 | GAA (0.43) | BLMMEN1KMT2ASMN1; SMN2PTPRE | |
| SCHEMBL6084065 | 0.78 | CNR1 (0.53) | BLMMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL6080568 | 0.78 | KMT2A (0.48) | BLMMEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1545523-A1 | 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS | Astex Technology Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004004720-A1 | 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | BLM 4296/4885MEN1 4610/4885KMT2A 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.